Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Robin, M; Giannotti, F; Deconinck, E; Mohty, M; Michallet, M; Sanz, G; Chevallier, P; Cahn, JY; Legrand, F; Rovira, M; Passweg, J; Sierra, J; Nguyen, S; Maillard, N; Yakoub-Agha, I; Linkesch, W; Cannell, P; Marcatti, M; Bay, JO; Chalandon, Y; Kröger, N; Gluckman, E; Rocha, V; Olavarria, E; Ruggeri, A; Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT).
Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.
Biol Blood Marrow Transplant. 2014; 20(11):1841-1846
Doi: 10.1016/j.bbmt.2014.06.011
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results. Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Cord Blood Stem Cell Transplantation - adverse effects
- Cord Blood Stem Cell Transplantation - methods
- Female -
- Fetal Blood -
- Hematopoietic Stem Cell Transplantation - methods
- Humans -
- Male -
- Middle Aged -
- Primary Myelofibrosis - therapy
- Transplantation Conditioning - methods
- Treatment Outcome -
- Unrelated Donors -
- Find related publications in this database (Keywords)
- Myelofibrosis
- Umbilical cord blood transplantation